Advancing Precision Genetic Medicine
Vesicor Therapeutics is dedicated to advancing the treatment of cancer through proprietary, non-viral, immune-silent delivery platforms and precision-engineered mRNA therapeutics. Our foundational science is focused on overcoming the biological barriers that have historically limited gene therapy, enabling the targeted re-activation of natural tumor suppression pathways.
The ecm-RV Delivery Platform
Historically, the delivery of genetic payloads has been constrained by the limitations of traditional vectors. Viral vectors frequently trigger immunogenic responses and face pre-existing immunity barriers. Conversely, synthetic Lipid Nanoparticles (LNPs) lack active cellular targeting and are limited by immune sensitization, which restricts safe, repeated administration.
Vesicor's engineered cellular microvesicle (ecm) and non-viral RNA vesicle (RV) platform is designed to address these fundamental barriers. By utilizing a non-viral architecture, the platform is engineered to be immune-silent. This approach is designed to facilitate enhanced cellular targeting, highly versatile cargo capacity, and the potential for repeated therapeutic dosing without triggering adverse immune responses.
Restoring Native Tumor Suppression
Our lead oncology program centers on the targeted delivery of p53 mRNA. Full-length p53 is a critical protein that triggers necessary tumor suppression mechanisms, including G1 cell cycle arrest and programmed cell death (apoptosis). Under cellularstress, cancer cells survive by utilizing repressor proteins that bind to the 3’ UTR tail of native p53 mRNA, shutting down standard translation and creating a stunted, ineffective p53 variant.
Vesicor utilizes a proprietary 3'-modified p53 mRNA designed to circumvent these cellular roadblocks. By engineering the payload to evade tumor-induced suppression, the platform is designed to force the high-yield translation of functional, full-length p53 directly inside the diseased cell.
Targeted Suppression via Transcriptional Interference
Vesicor’s proprietary vectors are designed to suppress tumor progression through a highly specific dual-action mechanism. Beyond standard p53-mediated apoptosis, in vitro co-transfection assays demonstrate that our lead clinical asset, pRBL-p53, induces profound transcriptional interference.
The introduction of the p53 transgene effectively monopolizes the cancer cell's transcriptional machinery. This resource competition significantly reduces the tumor cell's baseline gene expression, creating a highly specific, hostile microenvironment where tumor growth is suppressed.